SeekingAlpha · Aug 14, 2026
TN
NASDAQ · TNXP
Tonix Pharmaceuticals Holding Corp.
Healthcare · Biotechnology
$12.39
Up+$0.16 (+1.29%)
Updated Aug 21, 2026, 8:46 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 172.07M
- P/E ratio
- -2.71
- Dividend yield
- 0.00%
- 52-week range
- $9.40 – $17.00
- Volume
- 360.53K
- Avg. volume
- 886.98K
Price performance
TNXP price history
1M range · 21 trading sessions · Daily adjusted prices
TNXP closed at $12.39 after 21 trading sessions, up 16.67% for the selected period.
- Last close
- $12.39
- Period change
- +16.67%
- Period low
- $9.51
- Period high
- $12.73
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $12.66 | $12.79 | $12.3274 | $12.39 | 360.53K |
| Aug 19, 2026 | $12.67 | $13.16 | $12.6264 | $12.73 | 598.84K |
| Aug 18, 2026 | $12.41 | $12.83 | $12.2696 | $12.66 | 188.43K |
| Aug 17, 2026 | $12.72 | $12.84 | $11.97 | $12.66 | 388.99K |
| Aug 14, 2026 | $12.58 | $12.725 | $12.08 | $12.71 | 348.03K |
| Aug 13, 2026 | $12.00 | $12.74 | $11.79 | $12.50 | 557.78K |
| Aug 12, 2026 | $12.32 | $12.74 | $11.80 | $11.97 | 468.54K |
| Aug 11, 2026 | $12.80 | $12.825 | $11.95 | $12.34 | 497.17K |
| Aug 10, 2026 | $11.62 | $13.8905 | $11.05 | $12.59 | 1.5M |
| Aug 7, 2026 | $11.78 | $12.08 | $11.47 | $12.03 | 387.93K |
| Aug 6, 2026 | $11.27 | $11.695 | $11.15 | $11.65 | 227.56K |
| Aug 5, 2026 | $11.19 | $11.7067 | $11.11 | $11.26 | 261.56K |
| Aug 4, 2026 | $10.78 | $11.40 | $10.76 | $11.21 | 359.4K |
| Aug 3, 2026 | $10.11 | $10.69 | $9.96 | $10.665 | 347.82K |
| Jul 31, 2026 | $10.18 | $10.2133 | $9.58 | $10.01 | 468.29K |
| Jul 30, 2026 | $9.45 | $10.18 | $9.40 | $10.09 | 329.11K |
| Jul 29, 2026 | $10.00 | $10.31 | $9.43 | $9.51 | 544.59K |
| Jul 28, 2026 | $10.16 | $10.48 | $9.91 | $9.94 | 452.31K |
| Jul 27, 2026 | $10.00 | $10.58 | $9.99 | $10.37 | 403.54K |
| Jul 24, 2026 | $10.61 | $10.6599 | $9.81 | $9.88 | 715.38K |
| Jul 23, 2026 | $10.55 | $10.7099 | $10.38 | $10.62 | 379.39K |
Latest TNXP news
The latest Smart Investors Daily articles mentioning TNXP.
Stock researchCompany · Overview
TNXP research
Overview
Company profile and research snapshot.
Company profile
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 25, 2026 | Raymond James | Strong Buy | — |
| May 4, 2026 | TD Cowen | Buy | — |
| Mar 20, 2025 | Noble Capital Markets | Outperform | — |
| Jul 22, 2024 | Alliance Global Partners | Buy | — |
| Feb 28, 2024 | Dawson James | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Aug 11, 2026
Tonix Delivers A Beat, But The Real Test Starts Now
Tonix Pharmaceuticals (TNXP) reported strong 2Q26 results, with $13.5M revenue and early commercial traction for TONMYA, but remains in a spend-to-scale...
SeekingAlpha · Aug 10, 2026
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call August 10, 2026 8:30 AM EDTCompany ParticipantsDeborah ElsonSeth Lederman - Co-Founder,...
Benzinga · Aug 10, 2026
Tonix Pharmaceuticals Q2 EPS $(2.44) Beats $(2.64) Estimate, Sales $13.544M Beat $7.723M Estimate
Tonix Pharmaceuticals (NASDAQ:TNXP) reported quarterly losses of $(2.44) per share which beat the analyst consensus estimate of $(2.64) by 7.58 percent. This is a 36.79 percent increase over losses of $(3.86) per share
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
